Annual CFO
-$267.19 M
+$273.39 M+50.57%
December 31, 2024
Summary
- As of February 22, 2025, SAGE annual cash flow from operations is -$267.19 million, with the most recent change of +$273.39 million (+50.57%) on December 31, 2024.
- During the last 3 years, SAGE annual CFO has risen by +$110.99 million (+29.35%).
- SAGE annual CFO is now -140.22% below its all-time high of $664.28 million, reached on December 31, 2020.
Performance
SAGE Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$66.56 M
+$15.80 M+19.19%
December 31, 2024
Summary
- As of February 22, 2025, SAGE quarterly cash flow from operations is -$66.56 million, with the most recent change of +$15.80 million (+19.19%) on December 31, 2024.
- Over the past year, SAGE quarterly CFO has increased by +$13.88 million (+17.25%).
- SAGE quarterly CFO is now -106.58% below its all-time high of $1.01 billion, reached on December 31, 2020.
Performance
SAGE Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$267.19 M
+$52.96 M+16.54%
December 31, 2024
Summary
- As of February 22, 2025, SAGE TTM cash flow from operations is -$267.19 million, with the most recent change of +$52.96 million (+16.54%) on December 31, 2024.
- Over the past year, SAGE TTM CFO has increased by +$106.46 million (+28.49%).
- SAGE TTM CFO is now -136.59% below its all-time high of $730.29 million, reached on September 30, 2021.
Performance
SAGE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
SAGE Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +50.6% | +17.3% | +28.5% |
| 3 y3 years | +29.4% | +31.7% | +29.4% |
| 5 y5 years | +49.5% | +43.0% | +49.5% |
SAGE Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +50.6% | -75.9% | +56.7% | at high | +51.2% |
| 5 y | 5-year | -140.2% | +50.6% | -106.6% | +56.7% | -136.6% | +51.2% |
| alltime | all time | -140.2% | +50.6% | -106.6% | +56.7% | -136.6% | +51.2% |
Sage Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$267.19 M(-50.6%) | -$66.56 M(-19.2%) | -$267.19 M(-16.5%) |
| Sep 2024 | - | -$82.36 M(+2.4%) | -$320.15 M(-14.3%) |
| Jun 2024 | - | -$80.44 M(+112.6%) | -$373.65 M(-12.0%) |
| Mar 2024 | - | -$37.83 M(-68.3%) | -$424.74 M(-21.4%) |
| Dec 2023 | -$540.59 M(+17.5%) | -$119.52 M(-12.0%) | -$540.59 M(-1.4%) |
| Sep 2023 | - | -$135.87 M(+3.3%) | -$548.00 M(+3.2%) |
| Jun 2023 | - | -$131.52 M(-14.4%) | -$531.00 M(+5.0%) |
| Mar 2023 | - | -$153.68 M(+21.1%) | -$505.92 M(+10.0%) |
| Dec 2022 | -$460.04 M(+21.6%) | -$126.93 M(+6.8%) | -$460.04 M(+6.8%) |
| Sep 2022 | - | -$118.86 M(+11.7%) | -$430.61 M(+13.1%) |
| Jun 2022 | - | -$106.44 M(-1.3%) | -$380.57 M(+1.0%) |
| Mar 2022 | - | -$107.80 M(+10.6%) | -$376.90 M(-0.3%) |
| Dec 2021 | -$378.18 M(-156.9%) | -$97.50 M(+41.7%) | -$378.18 M(-151.8%) |
| Sep 2021 | - | -$68.83 M(-33.0%) | $730.29 M(+3.1%) |
| Jun 2021 | - | -$102.77 M(-5.8%) | $708.10 M(+2.3%) |
| Mar 2021 | - | -$109.09 M(-110.8%) | $691.88 M(+4.2%) |
| Dec 2020 | $664.28 M(-225.6%) | $1.01 B(-1210.8%) | $664.28 M(-243.3%) |
| Sep 2020 | - | -$91.02 M(-23.5%) | -$463.42 M(-7.5%) |
| Jun 2020 | - | -$118.98 M(-13.0%) | -$501.10 M(-2.8%) |
| Mar 2020 | - | -$136.69 M(+17.1%) | -$515.46 M(-2.5%) |
| Dec 2019 | -$528.71 M(+102.8%) | -$116.73 M(-9.3%) | -$528.71 M(+2.9%) |
| Sep 2019 | - | -$128.70 M(-3.5%) | -$513.76 M(+10.4%) |
| Jun 2019 | - | -$133.34 M(-11.1%) | -$465.24 M(+40.1%) |
| Mar 2019 | - | -$149.93 M(+47.3%) | -$332.03 M(+27.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$260.67 M(+18.9%) | -$101.78 M(+26.9%) | -$260.67 M(+19.7%) |
| Sep 2018 | - | -$80.19 M(>+9900.0%) | -$217.79 M(+18.6%) |
| Jun 2018 | - | -$135.00 K(-99.8%) | -$183.70 M(-24.3%) |
| Mar 2018 | - | -$78.57 M(+33.4%) | -$242.64 M(+10.7%) |
| Dec 2017 | -$219.28 M(+84.8%) | -$58.90 M(+27.8%) | -$219.28 M(+12.9%) |
| Sep 2017 | - | -$46.09 M(-22.0%) | -$194.15 M(+8.6%) |
| Jun 2017 | - | -$59.08 M(+7.0%) | -$178.86 M(+22.1%) |
| Mar 2017 | - | -$55.21 M(+63.5%) | -$146.45 M(+23.4%) |
| Dec 2016 | -$118.68 M(+67.9%) | -$33.78 M(+9.7%) | -$118.68 M(+15.2%) |
| Sep 2016 | - | -$30.80 M(+15.5%) | -$103.02 M(+12.3%) |
| Jun 2016 | - | -$26.67 M(-2.8%) | -$91.74 M(+9.9%) |
| Mar 2016 | - | -$27.43 M(+51.4%) | -$83.51 M(+18.2%) |
| Dec 2015 | -$70.68 M(+161.4%) | -$18.12 M(-7.2%) | -$70.68 M(+15.4%) |
| Sep 2015 | - | -$19.52 M(+5.8%) | -$61.23 M(+24.4%) |
| Jun 2015 | - | -$18.44 M(+26.3%) | -$49.20 M(+36.6%) |
| Mar 2015 | - | -$14.61 M(+68.5%) | -$36.03 M(+33.2%) |
| Dec 2014 | -$27.04 M(+54.4%) | -$8.67 M(+15.8%) | -$27.04 M(+15.5%) |
| Sep 2014 | - | -$7.49 M(+42.0%) | -$23.41 M(+11.0%) |
| Jun 2014 | - | -$5.27 M(-6.1%) | -$21.10 M(+5.0%) |
| Mar 2014 | - | -$5.62 M(+11.5%) | -$20.09 M(+14.7%) |
| Dec 2013 | -$17.52 M(+96.2%) | -$5.04 M(-2.6%) | -$17.52 M(+40.4%) |
| Sep 2013 | - | -$5.17 M(+21.2%) | -$12.48 M(+70.8%) |
| Jun 2013 | - | -$4.27 M(+40.3%) | -$7.31 M(+140.3%) |
| Mar 2013 | - | -$3.04 M | -$3.04 M |
| Dec 2012 | -$8.93 M | - | - |
FAQ
- What is Sage Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Sage Therapeutics?
- What is Sage Therapeutics annual CFO year-on-year change?
- What is Sage Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Sage Therapeutics?
- What is Sage Therapeutics quarterly CFO year-on-year change?
- What is Sage Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Sage Therapeutics?
- What is Sage Therapeutics TTM CFO year-on-year change?
What is Sage Therapeutics annual cash flow from operations?
The current annual CFO of SAGE is -$267.19 M
What is the all time high annual CFO for Sage Therapeutics?
Sage Therapeutics all-time high annual cash flow from operations is $664.28 M
What is Sage Therapeutics annual CFO year-on-year change?
Over the past year, SAGE annual cash flow from operations has changed by +$273.39 M (+50.57%)
What is Sage Therapeutics quarterly cash flow from operations?
The current quarterly CFO of SAGE is -$66.56 M
What is the all time high quarterly CFO for Sage Therapeutics?
Sage Therapeutics all-time high quarterly cash flow from operations is $1.01 B
What is Sage Therapeutics quarterly CFO year-on-year change?
Over the past year, SAGE quarterly cash flow from operations has changed by +$13.88 M (+17.25%)
What is Sage Therapeutics TTM cash flow from operations?
The current TTM CFO of SAGE is -$267.19 M
What is the all time high TTM CFO for Sage Therapeutics?
Sage Therapeutics all-time high TTM cash flow from operations is $730.29 M
What is Sage Therapeutics TTM CFO year-on-year change?
Over the past year, SAGE TTM cash flow from operations has changed by +$106.46 M (+28.49%)